A5071675822- Lymphoma Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Chronic Lymphocytic Leukemia Research
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Hematological disorders and diagnostics
- Cutaneous lymphoproliferative disorders research
- Acute Myeloid Leukemia Research
- Autoimmune Bullous Skin Diseases
- Animal Ecology and Behavior Studies
- Pulmonary Hypertension Research and Treatments
- Tissue Engineering and Regenerative Medicine
- Gastric Cancer Management and Outcomes
- Diabetes and associated disorders
- Hepatocellular Carcinoma Treatment and Prognosis
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Glycosylation and Glycoproteins Research
- Acute Lymphoblastic Leukemia research
- Blood disorders and treatments
- Carcinogens and Genotoxicity Assessment
- Wildlife Ecology and Conservation
- Cystic Fibrosis Research Advances
- CNS Lymphoma Diagnosis and Treatment
Azienda Ospedaliera S.Giuseppe Moscati
2019
New York Proton Center
2018
Columbia University Irving Medical Center
2018
Ospedale SS. Annunziata
1994
Centro di Riferimento Oncologico
1991
We report the outcomes in patients with muscle invasive bladder cancer from 2 institutions who experienced a clinically complete response to neoadjuvant platinum based chemotherapy and elected active surveillance. It was unknown whether conservative treatment could be safely implemented these patients.We retrospectively reviewed records of at our surveillance following transurethral resection tumors 2001 2017. A defined as absent tumor on post-chemotherapy tumor, negative cytology normal...
The risk of second primary cancer (SPC) was evaluated in 947 patients treated for Hodgkin's disease (HD) during the period January 1969 to December 1979. median follow-up this series 10.5 years (range, 9 19). Treatment categories included radiotherapy (RT) alone (115 patients, 12%), chemotherapy (CHT) (161 17%), combined RT plus CHT (381 40%), and salvage treatment resistant or relapsing HD (290 30.6%). Fifty-six SPCs were observed, occurring between 1 17 from initial treatment. Among these,...
AbstractNinety-nine patients with “standard risk” Stage IA-IIA Hodgkin's disease observed between January 1983 and December 1990, received radiotherapy only. The complete response rate was 98% (97/99). Twenty-one (21%) relapsed, 17 of whom (81%) obtained a second remission. projected 9-year overall survival disease-free were 95% 78%, respectively. In this study our goals to reduce the irradiation volumes, decrease number splenectomies performed at diagnosis, utilize alone in these patients....
You have accessJournal of UrologyBladder Cancer: Invasive V1 Apr 2018PD41-06 THE NATURAL HISTORY OF MUSCLE INVASIVE BLADDER CANCER PATIENTS WHO FOREGO IMMEDIATE RADICAL CYSTECTOMY AFTER NEOADJUVANT CHEMOTHERAPY Patrick Mazza, Justin Matulay, Stephanie Thompson, Dennis Robins, Alexa Meyer, Guarionex DeCastro, Christopher Anderson, and James McKiernan MazzaPatrick Mazza More articles by this author , MatulayJustin Matulay ThompsonStephanie Thompson RobinsDennis Robins MeyerAlexa Meyer...
4522 Background: Neoadjuvant platinum-based chemotherapy (NAC) followed by radical cystectomy (RC) is the gold standard treatment for muscle-invasive bladder cancer (MIBC). High morbidity and mortality associated with RC favorable survival outcomes seen in patients who exhibit a clinical complete response (cCR) to NAC forego has encouraged interest conservative management of MIBC. We report from two institutions experienced cCR opted surveillance only. Methods: Prospective enrollment...
Background: Carfilzomib, lenalidomide and dexamethasone (KRd) has been approved for the treatment of relapsed refractory multiple myeloma (RRMM) based on ASPIRE clinical trial. However, its effectiveness safety profile in real practice should be further assessed. Aims: We retrospectively evaluated 120 consecutive RRMM patients treated with KRd, 9 hematology departments Rete Ematologica Pugliese (REP), aim to evaluate efficacy KRd a world setting. Methods: Between December 2015 August...